Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06690047 · ClinicalTrials.gov registry record · Phase 4
Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)
A Phase 4 study, sponsored by Bernstein Clinical Research Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT06690047: Completed Phase 4 study, sponsored by Bernstein Clinical Research Center.
NCT06690047 is a Phase 4 study that has completed, run by Bernstein Clinical Research Center. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06690047, a Phase 4 study, has completed, sponsored by Bernstein Clinical Research Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
To assess the efficacy of recombinant human C1-esterase inhibitor in the management of HAE prodrome for preventing the progression from prodrome to an acute angioedema attacks. Subjects will either receive Ruconest after the first 2 prodromes or during the last 2 prodromes. 5 clinic visits will occur within 24 hours of a prodrome. Subjects will complete prodrome severity and angioedema attack diaries
Primary Outcome
A mixed model for repeated measures was used to determine the statistical significance of Conestat Alfa®'s clinical efficacy for treating the HAE prodrome versus the acute attack.
Interventions
- BIOLOGICAL Ruconest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 4 |
What the finished NCT06690047 record still lists
NCT06690047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Ruconest is the first listed.
NCT06690047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06690047 about?
NCT06690047 is a clinical study titled "Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)". To assess the efficacy of recombinant human C1-esterase inhibitor in the management of HAE prodrome for preventing the progression from prodrome to an acute angioedema attacks. Subjects will either receive Ruconest after the first 2 prodromes or during the last 2 prodromes. 5 clinic visits will occu...
What is the current status of trial NCT06690047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2018-08-14. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT06690047?
The interventions under investigation include: Ruconest (BIOLOGICAL).
Who is sponsoring clinical trial NCT06690047?
This trial is sponsored by Bernstein Clinical Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06690047's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI